The tools and techniques currently used to assay gene expression can be error-prone, time consuming and costly. Importantly, they represent a rate-limiting step in the effort to study new disease targets. For example, new target-specific antibodies must usually be created to probe every novel target of interest, and commonly used fluorescent fusion proteins can reliably track only ~30% of mammalian proteins, and cannot be used to reliably track targets with low expression, and secreted or membrane-bound targets.
By simultaneously monitoring multiple endogenous genes to assess drug efficacy, specificity, and adverse effects in living human single cells over time, our platform generates multi-metric and comprehensive effect profiles for any therapeutic modality, reducing the time and cost of early stages of drug discovery by more than tenfold.
Our proprietary technology obviates the need to use current techniques for screening and identification of drug candidates. Our streamlined workflow allows us to go from in silico target selection to drug screening in less than one month, allowing us to make key target suitability decisions more rapidly, and bring better therapeutic candidates to the clinic.